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 SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENTIAL  
5-HT7 RECEPTOR ANTAGONIST.  
by 
Shannon M. Sullivan 
Under the direction of Dr. Lucjan Strekowski 
 
ABSTRACT 
 The synthesis of a series of 2-chloropyrimidine derivatives is described. The synthesis 
began with a nucleophilic addition of lithiated heterocyclic molecules to the 4 position of 2-
chloropyrimidine to give dihydropyrimidine intermediates.  The intermediates were oxidized to 
the pyrimidine ring using the DDQ method. This was followed by an addition-elimination 
reaction of an amine to the 2-chloropyrimidine derivative. The structure and properties of the 
final compounds were analyzed by melting point, combustion analysis, and 13C-NMR and 1H-
NMR spectroscopy. Biological activities in vitro of the synthesized compounds as antagonists of 
the 5-HT2a and 5-HT7 receptors were determined by an independent laboratory. 
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Chapter 1 
 
Introduction 
 
 There are 14 identified subtype serotonin receptors which have been grouped into 7 
classes, (5-HT1-7).1-3 The most recently identified serotonin receptor is the 5-HT7 receptor.1-4 It 
has been identified in humans, rats, mouse, porcine and guinea pig.1-4 It is found in the central 
and peripheral nervous systems. The receptor is produced by a small group of neurons which are 
located in the brain stem and are able to send ascending and descending signals to a large part of 
the central nervous system.1-6 The functional roles of the receptor include thermoregulation, 
circadian rhythm, learning and memory, signaling in the hippocampus, sleep, smooth muscle 
relaxation of cerebral arteries and endocrine regulation.1-6,8 Preliminary studies on non-selective 
ligands have shown that the receptor may also play a functional role in mood regulation. 
Therefore, it is a potential target for novel drug development in the treatment of depression.1-3  
The receptor, along with all other 5-HT receptors, has a high affinity for serotonin along with 
other similarities, causing much difficulty in the identification of selective ligands. The ligands 
which are produced for this specific receptor should bind with high affinity and cause regulation 
of the specified 5-HT7 receptor.  
 
N
H
NH2
HO
 
Figure 1. 5-hydroxytryptamine (serotonin, 5-HT). 
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 The discovery of the 5-HT7 receptor was made concurrently by three different research 
groups in 1993; Ruat et al, Lovenberg et al, and Bard et al.1-3 It was found to be a seven-
transmembrane domain G-protein (Gs) coupled receptor (GPCRs). It is embedded within the cell 
membrane and positively coupled to the activation of adenylate cyclase.1-4,6-8 Distribution of the 
5-HT7 receptor has been studied by using autoradiography with [3H]5-CT as a radioligand, in 
situ low stringency hybridization, northern-blot analysis and reverse transcriptase polymerase 
chain reactions (RT-PCR).1,6  
 
Table 1. Amino acid change lengths of 5-HT7 splice variants.1,4-5 
   5-HT(7a)  5-HT(7b)  5-HT(7c)  5-HT(7d)  
Human 445 432  ­ 479 
Rat 448 435 470  ­ 
 
As shown in Table 1, four splice variants have been identified for the 5-HT7 receptor in 
human and rat tissue; 5-HT(7a), 5-HT(7b), 5-HT(7c) and 5-HT(7d). They vary in structure and length 
of their carboxy terminal chain due to alternative splicing but there is little difference between 
their function.1,4-5 Each of the species only expresses three of the four splice variants; two 
isoforms are homologous (5-HT(7a), 5-HT(7b))  and humans express 5-HT(7d).4 
There are many similarities of binding affinities between the 5-HT7 receptor and the 5-
HT(1) and 5-HT(2a) receptors. What once was thought of as a selective antagonist towards HT(1) 
and 5-HT(2a) receptors now shows moderate to high binding affinity towards the 5-HT7 receptor. 
The development of selective 5-HT7 receptor agonists and antagonists is crucial to help further 
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the knowledge of the physiological and pharmacological roles of this specific receptor. Studies 
performed by M. Kolaczkowski et al used molecular modeling techniques to better understand 
the binding of the 5-HT7 receptor. The group used a flexible docking technique and 5-HT(1a) as a 
reference  for the study due to similarities in affinity towards many ligands.8 Using 31 different 
known 5-HT7 receptor antagonists, two receptor-based pharmacophores were generated. The 
characteristics for high affinity binding towards the 5-HT7 receptor and the specific interactions 
with the binding pockets were proposed.8 The binding sites were found to be located along the 
transmembrane helix (TMH) with a central amino acid, asparagine, which acts as the main 
anchoring point for ligands.8 Two binding pockets were identified; TMH 4-6, buried within the 
receptor and TMH 7-3, located on the extracellular side. The important features identified for 
high affinity binding towards the 5-HT7 receptor include the interaction of a protonated nitrogen 
and an aromatic ring in the TMH 7-3 pocket, hydrogen bond acceptor or a hydrophobic aromatic 
group interacting with the TMH 4-6 pocket, and the ability of a terminal aromatic imide or amide 
for π-π stacking with phenylalanine and/or ion-π interactions with arganine.8 Among the 31 
different antagonists studied, the arylsulfonamidoalkylamides, shown in Figure 3, possess the 
most optimal geometry towards the 5-HT7 receptor. The aromatic group allows for π-π stacking 
with phenylalanine, the nitrogen possesses ion-π interactions with arganine, and the oxygen on 
sulfur can hydrogen bond with tyrosine. This general template has aided in the design of novel 
analogues of the pyrimidine based 5-HT7 ligands. The affinity towards the receptor is quantified 
by the study of the equilibrium between the receptor-inhibitor complex (Figure 2). The value 
reported as Ki is an equilibrium inhibitor constant indicating the ratio between the receptor-
inhibitor complex against the free receptors. The inhibitory effect is considered to increase with 
decreasing Ki values.9  
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RECEPTOR + INHIBITOR
K i RECEPTOR-INHIBITOR
K i = [R] [I]
[RI]
pKi = - log Ki  
Figure 2. The inhibitor constant, Ki.9  
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Figure 3. Arylsulfonamidoalkylamides used for binding study against the 5-HT7 receptor.8 
  
 
 
 
6 
 
N
H
H2N
NH2
O
5-CT pKi = 9.0
OH
N
8-OH DPAT pKi = 6.3
S
H3CS
N
N
Methiothepin pKi = 8.4
N
H
N
Cl
N
N
Clozapine pKi = 7.4
N
Amitryptiline pKi = 6.4  
Figure 4. Non-selective ligands towards the 5-HT receptor.2 
 
Most of what is known about the 5-HT7 receptor comes from the use of non-selective 
agonists and antagonists such as 5-carboxytryptamine (5-CT), 8-OH DPAT, methiopthepin, 
clozapine, and amitryptyline that are also selective 5-HT(1a/1d) receptor agonist (Figure 4).2 An 
agonist binds to a specific receptor and triggers a response in the cell which mimics the action of 
a hormone or neurotransmitter that binds to the same receptor. An antagonist will bind to a 
specific receptor, blocking the agonist from binding, and will not produce a response. Such non-
selective agonists and antagonists represent a class of antipsychotic and antidepressant drugs 
which have high or modest affinity for the 5-HT7 receptor (Table 2). Studies have shown that use 
of these drugs activates the release of the early Fos gene in to the suprachiasmatic nuclei (SCN) 
of the hypothalamus. Persistent use of these drugs showed a significant decrease in 5-HT7 
binding sites in the hypothalamus corresponding to a down-regulation of the 5-HT7 receptor.10  
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Table 2. Binding affinities for non-selective antipsychotic and antidepressant drugs towards the 
5-HT7 receptor.2 
 
    pKi   
  Rat Human 
Guinea 
Pig 
5-HT 8.8 8.1 9.0 
5-CT 9.8 9 9.4 
5-MeOT 9.2 8.3 9.0 
8-OH DPAT 7.5 6.3 7.3 
Methiothepin 9.4 8.4 8.0 
Clozapine 7.4 - - 
Amitriptyline 7.0 - - 
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Figure 5. SmithKline Beechman selective antagonists towards the 5-HT7 receptor.2 
 
 In 1994, a pharmaceutical company SmithKline Beechman patented a sulfonamide 
compound that had an affinity (pKi = 7.2) for the 5-HT7 receptor (Figure 5). Used as a reference 
compound, structural modifications were performed to SB1 by altering the chirality about the a 
and b carbons and the Structure-Activity Relationship (SAR) of the compounds was studied. 
Binding affinity studies showed that the R chirality on carbon a was necessary for high affinity to 
the 5-HT7 receptor. Alteration to the b chiral center by moving the methyl group to position 4 of 
the piperidine ring gives sulfonamide compound SB258719. Binding affinity studies showed 
SB258719 to have greater than 100-fold selectivity towards the 5-HT7 receptor. With a relatively 
high affinity, pKi = 7.5, it showed for the first promising selective ligand.2,4,7 
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Figure 6. SB269970; selective antagonist for the 5-HT7 receptor.4 
 
Further structural modifications and restraints to the selective antagonist SB258719 led to 
the discovery of another selective antagonistic compound SB269970 (Figure 6). The freely 
rotating side chain was incorporated into a piperidine or pyrrolidine substituent.4 The chiral 
center present on the piperidine ring in both SB2 and SB269970 showed importance for affinity 
to the 5-HT7 receptor and were used further in conformational analysis. Binding affinity studies 
showed that SB269970 had a high affinity for the 5-HT7 receptor with a pKi  = 8.9 and has 
greater than 25 fold selectivity over other 5-HT receptors; however it had some binding affinity 
to the 5-HT5A receptor, pKi  ≈ 7.2.4 SB269970 was further tested for the ability to stimulate 
adenylate cyclase in HEK 293 cells and showed antagonistic properties against the 5-HT7 
receptor. Although SB269970 showed great selectivity and inhibition, it showed for a poor drug 
candidate. This was due to its short life span in vivo caused by the phenol group.4 Researchers 
then decided to replace the phenol group with a variety of arenes to test for selectivity and 
bioavailability.   
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Figure 7. GlaxoSmithKline compound SB-656104.2  
 
GlaxoSmithKline have developed more metabolically stable compounds which resemble 
SB269970. The phenol group of SB269970 was replaced with arene groups to study the binding 
affinities against the 5-HT7 receptor. All the compounds showed a significant loss in binding 
affinity; a compound with a 6-methylindole group is the only one which came close to the 
SB269970 affinity (pKi = 8.9).2 GlaxoSmithKline then decided to replace the methyl group with 
arene groups; indole, benzimidazolone, and flurophenoxy showed greatest increase in affinity. 
The results showed a significant increase in binding affinities but also affinity for the adrenergic 
α1B receptor. Due to its high affinity for 5-HT7 receptor, lowered affinity for α1B receptor and 
bioavailability of 16%, SB-656104 was further studied. Compared to all the 5-HT receptors, SB-
656104 (Figure 7) showed greater than a 100 fold binding selectivity over all except the 5-HT1D, 
5-HT2A, and 5-HT2B  receptors.2    
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Figure 8. Kikuchi compounds with high affinity to 5-HT7 receptor.2,4,7 
  
 Another promising selective antagonist for the 5-HT7 receptor was synthesized by 
Kikuchi et al (Figure 8). A tetrahydrobenzindole derivative, DR4004, showed high affinity and 
selectivity towards the 5-HT7 receptor2,4,7. The antagonist DR4004 demonstrated a pKi of 8.67 
and compared with the 5-HT2 receptor, it showed a 47-fold selectivity towards the 5-HT7 
receptor 2,7. Such selectivity allowed for the determination that an aromatic group near the basic 
nitrogen is required to achieve such high selectivity. DR4004 was further evaluated with the 5-
HT1A, 5-HT2A, 5-HT4, 5-HT6, and D2 receptors. It was also found to be highly selective towards 
the 5-HT2 receptor. 
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Chapter 2 
 
Discussion 
 
 The protocol for the synthesis of the pyrimidine derivatives was developed by Strekowski 
et al at Georgia State University.11-13 Initial research on this project dealt with 2-, 4- and 6-
halogenopyrimidines reacting with commercially available organometallic reagents. The group 
went further to add organolithium reagents to generate 2,4-disubstituted pyrimidines and also to 
2,4,6-trisubstituted pyrimidines. 
 
n-BuLi
Br Li
(1)
1 2
THF, -78 °C
 
 
  The first step of the reaction consists of a bromine-lithium exchange reaction (Equation 
1) or a lithiation (Equation 2) of an organic molecule to generate the desired organolithium 
reagent.  Bromine lithium exchange was conducted in anhydrous THF at low temperatures under 
static pressure of nitrogen.  An excess of substrate 1 was used to ensure complete consumption 
of n-butyllithium.  The commercially available n-butyllithium acts as a strong nucleophile by 
displacing the bromine with lithium resulting in the desired organolithium reagent.  
 
13 
 
O
n-BuLi
3, 5: R1 =
(2)R
1-H R1-Li
5, 6
THF, -10 °C
4, 6: R1 =
3,4
 
 
  
Lithiation of compounds 3 and 4 occurred under much milder conditions in order to 
cleave the bond between carbon and hydrogen. In lithiation, the n-butyllithium acts as a base and 
will deprotonate the C-H bond and reestablish the bond with lithium. The process is reversible 
forming the more stable organolithium reagent. 
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Scheme 1. Synthesis of Compounds 10-12. 
 
N
N
Cl N
N
Cl
Li
H
R1 N
N
Cl
H
H
R1 N
N
ClR1
DDQ
10: R1 =
O
R1 -Li
(2, 5, 6)
7 8 9 10-12
11: R1 =
12: R1 =
H2O
 
 
 
 As shown in Scheme 1, 2-chloropyrimidine (7) was allowed to react with organolithium 
reagents 2, 5, and 6, in anhydrous THF. The corresponding dihydropyrimidine (9) intermediate 
was treated with 2,3- dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to reestablish the 
aromaticity of the pyrimidine ring. DDQ acts as an oxidation agent by the removal of two 
hydrogens and restoring the double bond in the ring. Extraction was performed using 
dichloromethane. The compounds were purified on a chromatotron using normal phase silica gel 
with a mobile phase of dichloromethane and ethyl acetate. The substituted pyrimidines 10-12 
were synthesized as shown in Scheme 1.  
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Scheme 2. Synthesis of Compound 14. 
 
N
N
Cl
1. H2O
2. DDQ
10
N
N
Cl
H
Li
13 14
Ph
Ph
Ph Ph
 
Compound 10 can be further substituted at the position 6 by a similar sequence of 
addition and oxidation reactions. Scheme 2 represents the second addition of organolithium 
reagent 5 to 2-chloro-4-(2-phenylethynyl)pyrimidine (10).  Quenching with water of the 
dihydropyrimidine intermediate 13 followed by treatment with DDQ gave 2-chloro-4,6-bis(2-
phenylethynyl)pyrimidine (14).  
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Scheme 3. Synthesis of Compounds 16-21.  
 
10 -12
amine; R2-H
Toluene, 100 °C N
N
N
N
R1 R2
H
R1
Cl
R2
15
16-21
16: R1 = R2 = NN Me
17: R1 = R2 = ON
18: R1 = R2 = NHN
19: R1 = R2 = NHN
O
20: R1 = R2 = NN
O
Me
21: R1 = R2 = NN Me
 
 
 
The synthesis of new pyrimidine derivatives 16-21 is shown in Scheme 3. The chloride 
displacement reaction was conducted in toluene under reflux for 24 h.  
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Scheme 4. Synthesis of Compound 23. 
 
11
Toluene, 100 °C
N
NH2
N
N
H
Cl
NH
N
N
N
NH
N
O O
22 23  
 
 The synthesis of 4-(2-Furyl)-N-(2-(pyrrolidino)ethyl)pyrimidin-2-amine (23) through the 
intermediate of 22 is shown in Scheme 4.  
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Scheme 5. Synthesis of Compound 25. 
 
 
14
N
N
Toluene, 100 °C
H
N
Cl
N N Me
N
Me
Ph
Ph
N
N
Ph
Ph
N
N
Me
24
25
 
  
Following the same protocol, addition of excess N-methylpiperazine to 2-chloro-4,6-
bis(2-phenylethynyl)pyrimidine (14) was conducted in toluene under reflux for 24 h. Elimination 
of chloride from the intermediate adduct 24 gave 2-(4-methylpiperazinyl)-4,6-bis(2-
phenylethynyl)pyrimidine (25) in good yield. 
 
 
 
 
 
 
 
 
 
 
19 
 
Scheme 6. Synthesis of Compound 28. 
 
11
HN NH HN N
N
N
O
H
Cl
NN
N
N
O
H
Cl
N
N
O
NN
N
N
O
N
N
O
26 27
28  
 
A similar synthesis of 28 is shown in Scheme 6. The reaction was conducted in toluene 
under reflux for 2 hrs.  First piperazine attacks the electrophilic carbon on the pyrimidine ring. 
After displacement of the chloride, excess 2-chloro-4-(2-furyl)pyrimidine (11) attacks the second 
electrophilic carbon allowing for a second nucleophilic addition reaction to occur. The final 
product is 1,4-Bis[4-(furan-2-yl)pyrimidin-2-yl]piperazine (28).  
All substituted pyrimidines, 16-21, 23, 25 and 28 were evaluated by proton NMR and 
combustion analysis experiments.  
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Chapter 3. 
 
Biological Activity 
  
 The substituted pyrimidine compounds have shown high to moderate affinity towards the 
5-HT7 receptor along with the 5-HT2A receptor. The pKi values (Ki is inhibition constant, pKi =  
-log Ki) reported show inhibition towards the specific receptors. The receptors were tested using 
a radioligand binding assay method. The 5-HT2A binding assays used rat cortical membranes, 
[3H]-ketanserin and methysergide for nonspecific binding. The 5-HT7 binding assays were 
performed using 5-HT7b cloned mammalian cDNA introduced into human embryonic kidney 
cells (HEK 293) using [3H]-CT saturation binding studies along with cAMP accumulation 
assays.13  
 The biological activity of the synthesized compounds 16, 20, 23, 25 and 28, are reported 
in Table 3. Activity showed a moderate affinity for the 5-HT7 receptor with pKi’s ranging from 
5.09-6.00. The compounds showed a higher affinity towards the 5-HT2A receptor with pKi’s 
ranging from 5.13-6.25.  
 
 
 
 
 
 
 
21 
 
Table 3. Biological Activity of Ligands 16, 20, 23, 25 and 28.  
Compound   
pKi  
5-HT2A 
pKi  
5-HT7 
16 
 
− 5.77 
20 
 
6.25 5.99 
23 
 
5.13 5.09 
25 
 
− 6.00 
28 
 
5.76 5.27 
 
 
N
N
N
N
Me
N
N
N
N
Me
O
N
N
NH
N
O
N
N
N
N
Me
NN
N
N
O
N
N
O
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Chapter 4.  
 
Experimental 
 
General 
 
 All reactions with organolithium reagents were conducted in tetrahydrofuran (THF) 
under static pressure of nitrogen. The glassware was cleaned and dried with heat, assembled hot 
and cooled in a stream of nitrogen. All liquid reagents were transferred with syringes.  
Melting points were measured (open Pyrex capillary) on a Mel-Temp® and are 
uncorrected. Nuclear magnetic resonance (NMR) spectra were recorded on Varian Unity+ 
operating at 300 MHz and 400 MHz instrument at 25 °C using tetramethylsilane as an internal 
standard. NMR samples were prepared in 0.7 mL of CDCl3 (Aldrich) in 5 mm NMR tubes. 
Chemical analysis was taken on a Perkin Elmer® Series II CHNS/O Analyser 2400 instrument.  
 
Lithiation 
 
 Reagent 2 was generated by a bromine-lithium exchange reaction of 2-bromo-1,1-
biphenylethyl with n-butyllithium (Aldrich, 2.5 M in hexanes, 2 mmoles) at a temperature of -78 
°C for 30 min. 2-Phenylethynyllithium (5) and 2-furanyllithium (6) were generated by a 
lithiation reaction of phenylacetylene and furan, respectively, using n-butyllithium (Aldrich, 2.5 
M in hexanes, 2 mmoles) at -78 °C and -10 °C for 2 hours. 
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Preparation of 2-chloro-4-(heteroaryl)pyrimidines:11-13 
 
A solution of a heteroaryllithium reagent R1-Li was prepared as described above. The 
solution was treated dropwise at -78 °C with 2-chloropyrimidine (0.23g, 2 mmoles) in THF (5 
mL). The mixture was stirred for 3 hours until the temperature reached -30 °C. The progress of 
the reaction was monitored by TLC on silica gel, eluting with dichloromethane:hexanes (1:1), 
until 2-chloropyrimidine was consumed. The mixture was then quenched with deionized water 
(0.5 mL) and treated with a solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 1 g, 2 
mmoles) in THF (5 mL). Once the mixture reached room temperature, a mixture of sodium 
hydroxide (3 M, 5 mL, 2 mmoles) was added and stirred. The mixture was rinsed with THF and 
hexanes. The organic layer was dried with anhydrous magnesium sulfate and purified by silica 
gel column chromatography with hexanes/dichloromethane/ethyl acetate as an eluent to give 10-
12, and 14.  
 
Amination 
 
The 2-chloro-4-(heteroaryl)pyrimidines 10-14 were allowed to react with an excess 
amount of an amine R2-H.  The mixture was covered by septum and allowed to react for 24 h at 
room temperature unless specified otherwise. The reaction progress was monitored by TLC, 
eluting with dichloromethane:hexanes (1:1), until the 2-chloro-4-(heteroaryl)pyrimidine 10-14 
was consumed.  
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Workup 
 
The reaction was then quenched with deionized water (0.5 mL) and a solution of sodium 
carbonate (0.1 g, 2 mmoles) was added to neutralize with HCl. The mixture was then rinsed with 
hexanes and ether. Anhydrous magnesium sulfate was added to the organic layer for drying. The 
product was purified by silica gel column chromatography with hexanes/dichloromethane/ethyl 
acetate as an eluent to give 16-21, 23, 25 and 28. 
 
Salt Formation 
 
Compounds 16, 17, 20-23, 25 and 28 were dissolved in minimal amount of methanol and 
treated with excess hydrobromic acid to form the hydrobromide salt. The salt was collected from 
diethyl ether using vacuum filtration to give compounds 16, 17, 20, 21, 23, 25 and 28, 
respectively. Compounds 18 and 19 hydrolyzed when trying to convert to a salt. 
All salts were sent to A.J. Bojarski et al at the Polish Academy of Science in Krakow, 
Poland for biological testing.  
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Detailed Procedures and Characterization 
 
2-Chloro-4-(2-phenylethynyl)pyrimidine (10) 
While under N2 pressure and a temperature of -78 °C, n-butyllithium (2.5 M, 1.57 mL, 
3.9 mmoles) was added to phenylacetylene (0.401 g, 3.93 mmol) dissolved in THF (10 mL). The 
reaction mixture was held at a steady temperature of -78 °C for 30 minutes. Then, a solution of 
2-chloropyrimidine 7 (0.30 g, 2.62 mmoles) in THF (3 mL) was added to the above mixture. The 
temperature was allowed to reach -30 °C over 3 hours. Workup according to general method 
described above yielded 0.15 g (0.47 mmol, 37%) of 2-chloro-4,6-bis(2-
phenylethynyl)pyrimidine (10). 
This compound had mp 102-105 °C; 1H-NMR (300 MHz, CDCl3): δ 8.65 (d, 1H, J = 5.1 Hz), 
7.66 (d, 1H, J = 3.0 Hz), 7.64 (d, 1H, J = 3.9 Hz), 7.46 (m, 4H). 13C-NMR (300 MHz, CDCl3): δ 
161.85, 159.67, 153.58, 132.83, 130.68, 128.91, 121.94, 120.86, 96.48, 86.10. 
 
2-Chloro-4-(2-furyl)pyrimidine (11)12 
Compound prepared as described in literature12. While under N2 pressure and a 
temperature of -10 °C, of n-butyllithium (2.5 M, 2.6 mL, 6.5 mmol) was added to excess furan 
(1.70 g, 25 mmol) dissolved in THF (10 mL). The reaction mixture was held at a steady 
temperature of -10 °C for 2 hours. Then, a solution of 2-chloropyrimidine 7 (0.69 g, 6.0 mmoles) 
in THF (3 mL) was added to the above mixture. The progress of the reaction was monitored by 
TLC on silica gel, eluting with dichloromethane:hexanes (1:1). Workup according to general 
method described above yielded 0.17 g (0.95 mmol, 25%) of 2-chloro-4-(2-furanyl)pyrimidine 
(11). 
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This compound had mp 102–104 °C12; 1H-NMR (400 MHz, CDCl3): δ 8.35 (d, 1H, J = 4.8 Hz), 
7.55 (m, 1H), 7.15 (t, 1H, J = 3.2 Hz), 6.86 (d, 1H, J = 4.8 Hz), 6.53 (m, 1H).  
Compared to literature values of mp 102-104 °C; 1H-NMR (Free base, 300 MHz, CDCl3): δ 8.59 
(d, 1H, J = 5.4 Hz), 7.63 (d, 1H, J = 1.8 Hz), 7.53 (d, 1H, J = 5.4 Hz), 7.39 (d, 1H, J = 3.6 Hz), 
6.61 (dd, 1H, J = 3.6 Hz, 1.8 Hz). 
 
2-Chloro-4-(biphen-2-yl)pyrimidine (12) 
While under N2 pressure and a temperature of -78 °C, (2.5 M, 0.8 mL, 2 mmol) of n-
butyllithium was added to 2-bromobiphenyl (0.47 g, 2 mmol) dissolved in THF (5 mL).Then, a 
solution of 2-chloropyrimidine 7 (0.23 g, 2 mmol) dissolved in THF (3 mL) was added. The 
progress of the reaction was monitored by TLC on silica gel, eluting with 
dichloromethant:hexanes (1:1). The mixture was and allowed to reach -30 °C over 2 hours. 
Workup according to general method described above yielded 0.12 g (44 mmol, 51%) of 2-
chloro-4-(biphenyl)pyrimidine (12). 
This compound was a yellow oil; 1H-NMR (400 MHz, CDCl3): δ 8.23 (d, 1H, J = 5.2 Hz), 7.83 
(t, 1H, J = 7.6 Hz), 7.53 (m, 2H), 7.46 (d, 1H, J = 1.6 Hz), 7.32 (m, 3H), 7.19 (m, 2H), 6.70 (d, 
1H, J = 5.2 Hz). 
 
2-Chloro-4,6-bis(2-phenylethynyl)pyrimidine (14) 
While under N2 pressure and a temperature of -78 °C, (2.5 M, 1.57 mL, 3.9 mmoles) of 
n-butyllithium was added to phenylacetylene (0.40 g, 3.9 mmol) dissolved in THF (10 mL). The 
mixture was held at a steady temperature of -78 °C for 30 minutes. Then, a solution of 2-
chloropyrimdine 7 (0.30 g, 2.62 mmol) in THF (3 mL) was added to the mixture. The 
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temperature was allowed to reach -30 °C over 3 hours. Workup according to general method 
described above yielded 0.15 g (0.47 mmol, 37%) of 2-chloro-4,6-bis(2-
phenylethynyl)pyrimidine (14). 
This compound had a mp 150-152 °C, yield 37 %; 1H-NMR (300 MHz, CDCl3): δ 7.64 (m, 4H) 
7.52 (s, 1H), 7.38 (m, 6H). 13C-NMR (300 MHz, CDCl3): δ 161.78, 153.42, 132.87, 130.75, 
128.94, 124.07, 120.86, 96.98, 86.09.  
 
2-(4-Methylpiperazino)-4-(2-phenylethynyl)pyrimidine dihydrobromide (16•2HBr•H2O) 
To the 2-chloropyrimidine product 10 (0.05 g, 0.23 mmol), dissolved in toluene (1.5 mL), 
excess 1-methylpiperazine (0.07 g, 6.7 mmol) was added. The reaction was allowed to react at 
room temperature for 24 hours.  Workup corresponding to general method described above 
yielded 0.0014 g (0.005 mmol, 2.1 %) of 16. 
This compound had mp 193-195 °C; 1H-NMR (Free base, 300 MHz, CDCl3): δ 8.29 (d, 1H, J = 
4.8 Hz), 7.59 (d, 2H, J = 4 Hz), 7.36 (m, 3H), 6.67 (d, 1H, J = 4.8 Hz), 3.88 (t, 4H, J = 7.2 Hz), 
2.47 (t, 4H, J = 4.8 Hz), 2.34 (s, 3H). 13C-NMR (Free base, 300 MHz, CDCl3): δ 161.86, 158.10, 
151.41, 132.53, 129.70, 128.67, 121.95, 112.61, 91.58, 87.97, 55.23, 46.51, 43.93. 
Analysis. Calculated for C17H18N4•2HBr•H2O: C, 44.56, H, 4.84, N, 12.23. Found: C, 44.08, H, 
4.82, N, 11.94. 
 
2-Morpholino-4-(2-phenylethynyl)pyrimidine dihydrobromide (17•2HBr•0.5H2O) 
To the 2-chloropyrimidine product 10 (0.058 g, 0.27 mmol) dissolved in toluene (1.5 
mL), excess morpholine (0.70 g, 8.07 mmol) was added and refluxed. After 15 minutes, workup 
corresponding to general method yielded 0.074 g (0.28 mmol, 11 %) of 17. 
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This compound had mp 207-209 °C; 1H-NMR (Free base, 400 MHz, CDCl3): δ 8.33 (d, 1H, J = 
5.1 Hz), 7.62 (m, 2H), 7.41 (t, 3H, J = 3.0 Hz), 6.74 (d, 1H, 5.1), 3.85 (m, 4H), 3.80 (m, 4H). 
13C-NMR (Free base, 300 MHz, CDCl3): δ 161.86, 158.10, 151.42, 132.54, 129.71, 128.68, 
121.96, 112.61, 91.58, 87.97, 55.28, 43.92. 
Analysis. Calculated for C16H21N3O•2HBr•0.5H2O: C, 44.06; H, 4.16; N, 9.63. Found: C, 43.09; 
H, 3.97; N, 9.53. 
 
4-(2-Phenylethynyl)-2-(piperazino)pyrimidine (18) 
To the 2-chloropyrimidine product 10 (0.150 g, 0.699 mmol), dissolved in toluene (1.5 
mL), excess piperazine (0.60 g, 8.07 mmol) was added and refluxed. After 15 minutes, workup 
corresponding to general method described above yielded 0.02 g (0.005 mmol, 3.34 %) of 18. 
This compound was a yellow oil; 1H-NMR (400 MHz, CDCl3): δ 8.31 (d, 1H, J = 4.8 Hz), 7.59 
(m, 2H), 7.38 (t, 3H, J = 1.2 Hz), 6.66 (d, 1H, J = 4.8 Hz), 3.84 (m, 4H), 2.94 (m, 4H). 
 
4-(2-Furyl)-2-(piperazino)pyrimidine (19) 
At room temperature, excess piperazine (0.05 g, 0.63 mmol) was added to 2-
chloropyrimidine product 11 (0.32 g, 1.75 mmol), dissolved in toluene (1 mL) and of methanol 
(1 mL). The mixture was refluxed for 2 hours and allowed to react at room temperature for 24 
hours. Workup corresponding to general method described above yielded 0.05 g (0.22 mmol, 95 
%) of 19.  
This compound was a brown oil; 1H-NMR (Free base, 400 MHz, CDCl3): δ 8.39 (d, 1H, J = 5.2 
Hz), 7.57 (m, 1H), 7.20 (m, 1H), 6.91 (d, 1H, J = 5.2 Hz), 6.56 (s, 1H), 3.99 (s, 4H), 2.05 (s, 1H). 
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4-(2-Furyl)-2-(4-methylpiperazino)pyrimidine dihydrobromide (20•1.75HBr•0.25H2O)13 
Compound prepared as described in literature13. At room temperature, excess 1-
methylpiperazine (0.18 g, 1.83 mmol) was added to the pyrimidine product 11 (0.11 g, 0.61 
mmol) dissolved in toluene (1mL). After 24 hours, workup corresponding to general method 
described above yielded 0.14 g (0.58 mmol, 78 %) of 20. 
This compound had a mp 234-236 °C; 1H-NMR (Free base, 400 MHz, CDCl3): δ 8.34 (d, 1H, J 
= 5.2 Hz), 7.54 (m, 1H), 7.15 (t, 1H, J = 3.6 Hz), 6.86 (d, 1H, J = 5.2 Hz), 6.54 (m, 1H), 3.90 (t, 
4H, J = 5.2 Hz), 2.48 (t, 4H, J = 5.2 Hz), 2.34 (s, 3H). 13C-NMR (Free base, 400 MHz, CDCl3): 
δ 161.64, 158.29, 155.85, 152.69, 144.35, 112.08, 111.17, 103.93, 54.99, 46.26, 43.64. 
Compared to literature values of mp 270-273 °C; 1H-NMR (Free base, 300 MHz, CDCl3): δ 8.38 
(d, 1H, J = 5.5 Hz), 7.60 (m, 1H), 6.88 (d, 1H, J = 5.5 Hz), 6.55 (m, 1H), 3.95 (m, 4h), 2.50 (m, 
4H), 2.40 (s, 3H). 
Analysis. Calculated for C13H16N4O•1.75HBr•0.25H2O: C, 40.00; H, 4.71; N, 14.35;  
Found: C, 40.43; H, 4.70; N, 14.31. 
 
4-(Biphen-2-yl)-2-(4-methylpiperazino)pyrimidine dihydrobromide (21•2HBr•H2O) 
At room temperature, excess 1-methylpiperazine (0.13 g, 1.31 mmol) was added to the 
pyrimidine product 12 (0.12 g, 0.44 mmol) dissolved in toluene (1 mL). After 24 hours, workup 
corresponding to general method described above yielded 0.12 g (0.35 mmol, 86 %) of 21. 
This compound had a mp 85-87 °C; 1H-NMR (Free base, 400 MHz, CDCl3): δ 8.09 (d, 1H, J = 
5.0 Hz), 7.70 (s, 1H), 7.44 (m, 3H), 7.25 (m, 3H), 6.29 (d, 1H, J = 5.0 Hz), 3.68 (d, 4H, J = 4.0 
Hz), 2.37 (t, 4H, J = 4.8 Hz), 2.04 (s, 1H). 13C-NMR (Free base, 400 MHz, CDCl3): δ 166.87, 
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161.56, 157.00, 141.65, 141.33, 137.89, 130.95, 130.10, 129.39, 128.06, 127.54, 126.76, 110.48, 
54.98, 46.28, 43.53, 14.22. 
Analysis. Calculated for C21H22N4•2HBr•H2O: C, 49.43; H, 5.14; N, 10.98. Found: C, 48.32; H, 
5.0; N, 10.57. 
 
4-(2-Furyl)-N-(2-(pyrrolidino)ethyl)pyrimidine-2-amine dihydrobromide (23•2HBr) 
At room temperature, excess 1-(2-aminoethyl)-pyrrolidine (0.47 g, 4.1 mmol) was added 
to pyrimidine product 11 (0.12 g, 0.69 mmol) dissolved in toluene (1 mL). The mixture was 
refluxed for 16 hours. Workup corresponding to general method described above yielded 0.13 g 
(0.49 mmol, 27 %) of 23. 
This compound had a mp 173-175 °C; 1H-NMR (Free base, 400 MHz, CDCl3): δ 8.30 (d, 1H, J 
= 5.2 Hz), 7.55 (t, 1H, J = 1.6 Hz), 7.14 (d, 1H, J = 3.6 Hz.), 6.87 (m, 1H), 6.53 (m, 1H), 5.72 (s, 
1H), 3.57 (m, 2H), 2.72 (t, 2H, J = 6.4 Hz), 2.56 (m, 4H), 1.78 (m, 4H).  
13C-NMR (Free base, 400 MHz, CDCl3): δ 162.39, 158.50, 156.11, 152.39, 144.43, 112.10, 
111.33, 104.50, 54.82, 53.90, 40.17, 23.54. 
Analysis. Calculated for C14H18N4O•2HBr: C, 40.02; H, 4.80; N, 13.34. Found: C, 40.15; H, 
4.90; N, 13.30. 
 
2-(4-Methylpiperazino)-4,6-bis(2-phenylethynyl)pyrimidine dihydrobromide 
(25•2HBr•0.5H2O) 
At room temperature, excess 1-methylpiperazine (0.05 g, 0.48 mmol) was added to 2-
chloropyrimidine product 14 (0.05 g, 0.16 mmol). After 24 hours, the reaction progress was 
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monitored by TLC, eluting with dichloromethane:hexanes (1:1). Workup corresponding to 
general method described above yielded 0.0014 g (0.004 mmol, 2.9 %) of 25. 
This compound had mp 167-169°C; 1H-NMR (Free base, 300 MHz, CDCl3): δ 7.63 (m, 4H), 
7.43 (m, 6H), 6.92 (s, 1H), 3.96 (t, 4H, J = 9.9), 2.51 (t, 4H, J = 9.9), 2.38 (s, 3H).  
13C-NMR (Free base, 400 MHz, CDCl3): δ 161.96, 151.65, 132.58, 129.80, 128.71, 121.91, 
115.27, 92.14, 87.80, 55.27, 46.48, 43.98. 
Analysis. Calculated for C25H22N4•2HBr•0.5H2O: C, 54.66; H, 4.59; N, 10.20. Found: C, 54.85; 
H, 4.39; N, 10.21. 
 
1,4-Bis[4-(furan-2-yl)pyrimidin-2-yl]piperazine dihydrobromide (28•2HBr•H2O) 
 To the pyrimidine product 11 (0.17 g, 0.95 mmol), dissolved in toluene (1.5 mL), excess 
piperazine (0.02 g, 0.20 mmol) was added and refluxed for 2 hours. The reaction progress was 
monitored by TLC, eluting with dichloromethane. Workup corresponding to general method 
described above yielded 0.004 g (0.007 mmol, 23 %) of 28.  
This compound had a mp 328-330 °C; 1H-NMR (Free base, 400 MHz, CDCl3): δ 8.38 (d, 1H, J 
=5.2 Hz), 7.57 (t, 2H, J = 1.6 Hz), 7.19 (d, 2H, J = 3.2 Hz), 6.89 (d, 2H, J = 4.8 Hz), 6.55 (m, 
2H), 3.99 (s, 8H). 13C-NMR (Free base, 400 MHz, CDCl3): δ 161.76, 158.38, 155.94, 152.68, 
144.44, 112.15, 111.30, 104.15, 43.69. 
Analysis. Calculated for C20H18N6O3•2HBr•H2O: C, 44.06; H, 3.88; N, 15.41. Found: C, 44.10; 
H, 3.26; N, 15.22. 
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